CPIC Guideline Update: Carbamazepine, Oxcarbazepine and HLA genotype

The CPIC Guideline for carbamazepine, oxcarbazepine and HLA genotype is now published in Clinical Pharmacology and Therapeutics. The accepted article can be viewed on the PharmGKB pages for carbamazepine and oxcarbazepine and on the CPIC website.

Carbamazepine and oxcarbazepine are anticonvulsants which have been approved for treatment for epilepsy and, in the case of carbamazepine, trigeminal neuralgia. Patients with the HLA-A*31:01 and/or the HLA-B*15:02 allele have a significantly increased risk of carbamazepine-induced cutaneous adverse reactions, while patients with the HLA-B*15:02 allele have a significantly increased risk of oxcarbazepine-induced cutaneous adverse reactions.
The CPIC guideline and supplement summarize evidence from the literature and provide therapeutic recommendations for carbamazepine and oxcarbazepine based on HLA genotype. This guideline is and update of the 2013 guideline for carbamazepine and HLA-B genotype and now includes prescribing information for oxcarbazepine and HLA-B and new prescribing information for carbamazepine and HLA-A genotype.

For further details see the guidelines and supplement on CPIC, or on the pages for carbamazepine and oxcarbazepine on PharmGKB.

Subscribe to ClinPGx Blog

Don’t miss out on the latest issues. Sign up now to get access to the library of members-only issues.